European Medicines evaluation Agency bans dextropropoxyphene: A landmark decision for clinical toxicology?

Clinical Toxicology

Volumn 47, Issue 8, 2009, Pages 782-783

  Bateman, Nicholas D ^a   Sandilands, Euan A ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Dextropropoxyphene; Medicines regulation; Overdose; Poisons Centres; Toxicovigilance

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CODEINE; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIHYDROCODEINE; DOSULEPIN; OPIATE; PARACETAMOL; QUININE; SODIUM CHANNEL BLOCKING AGENT;

BLINDNESS; CLINICAL DECISION MAKING; DRUG MARKETING; DRUG OVERDOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; LEG CRAMP; MEDICAL ASSESSMENT; MORTALITY; NOTE; POISON CENTER; PUBLIC HEALTH; SUDDEN DEATH; SUICIDE;

ACETAMINOPHEN; ANALGESICS, OPIOID; CONSUMER PRODUCT SAFETY; DEXTROPROPOXYPHENE; DRUG AND NARCOTIC CONTROL; DRUG COMBINATIONS; EUROPE; GOVERNMENT REGULATION; HUMANS; OVERDOSE; POISON CONTROL CENTERS; PRESCRIPTION DRUGS; RISK ASSESSMENT; SUICIDE; TOXICOLOGY;

EID: 70350361971     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650903218757     Document Type: Note

References (14)

1. Li Wan PA, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997; 315:1565-1571.
2. Whittington RM. Dextropropoxyphene deaths: a coroner's report. Hum Toxicol 1984; 3(Suppl.):175S-185S.
3. Afshari R, Good AM, Maxwell SRJ, Bateman DN. Co-proxamol overdose is associated with a 10-fold excess mortality compared with other paracetamol combination analgesics. Br J Clin Pharmacol 2005; 60:444-447.
4. Afshari R, Maxwell S, Dawson A, Bateman DN. ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning. Clin Toxicol 2005; 43:255-259.
5. Medicines and Healthcare Products Regulatory Agency. Coproxamol to be withdrawn from the market. http://www.mhra.gov.uk/Safetyinformation/ Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/ CON1004254. Accessed 31 January 2005.
6. Jonasson B, Jonasson U, Saldeen T. Suicides may be overreported and accidents underreported among fatalities due to dextropropoxyphene. J Forensic Sci 1999; 44:334-338.
7. http://www.lakemedelsverket.se/Alla-nyheter/NYHETER-2005/ Fastakombinationer- av-smartstillande-lakemedel-innehallande-dextropropoxifen- forsvinner-fran-marknaden-under-hosten-2005/. Accessed 23 July 2009 (in Swedish).
8. Sandilands EA, Bateman DN. Co-proxamol withdrawal has reduced suicide from drugs in Scotland. Br J Clin Pharmacol 2008; 66:290-293.
9. Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, Smith KL, Kapur N, Gunnell D. Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis. BMJ 2009; 338:b2270.
10. EMEA Press release 401062/2009. European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines.
11. Food and Drug Administration. FDA takes actions on Darvon, other pain medications containing propoxyphene. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm170769.htm. Accessed 24 July 2009.
12. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997; 16:374-390.
13. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med 2003; 96:369-374.
14. Langford NJ, Good AM, Laing WJ, Bateman DN. Quinine intoxications reported to the Scottish Poisons Information Bureau 1997-2002: a continuing problem. Br J Clin Pharmacol 2003; 56:576-578.